NCT01187199 2026-04-16
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
224 trialsNCT04879121 2026-04-16
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05564377 2026-04-16
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05638295 2026-04-16
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07193511 2026-04-16
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07229313 2026-04-16
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
Phase 1 Recruiting
NCT07361133 2026-04-16
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
Phase 2 Not yet recruiting
NCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
NCT01630733 2026-04-15
ENSPIRIT
Achieve Life Sciences
Phase 3 Completed
NCT02387905 2026-04-15
Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03525873 2026-04-15
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT03671226 2026-04-15
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT04053517 2026-04-15
Financial Distress in Advanced Cancer Patients
M.D. Anderson Cancer Center
Active not recruiting
NCT04534205 2026-04-15
AHEAD-MERIT
BioNTech SE
Phase 2/3 Recruiting
NCT04693377 2026-04-15
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT04957615 2026-04-15
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05091632 2026-04-15
Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit
M.D. Anderson Cancer Center
Suspended
NCT06803680 2026-04-15
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06933329 2026-04-15
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
BicycleTx Limited
Phase 2 Active not recruiting
NCT06974110 2026-04-15
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
NCT07094204 2026-04-15
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT07458347 2026-04-15
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Phase 1 Recruiting
NCT00068003 2026-04-14
Harvesting Cells for Experimental Cancer Treatments
National Institutes of Health Clinical Center (CC)
Enrolling by invitation
NCT01642017 2026-04-14
VOTRAGE
Institut Claudius Regaud
Phase 1 Terminated
NCT02857400 2026-04-14
CREDO
Institut Claudius Regaud
Phase NA Completed
NCT03483337 2026-04-14
New MRI Biomarkers in Head and Neck Cancers
Memorial Sloan Kettering Cancer Center
Recruiting
NCT03841617 2026-04-14
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04927416 2026-04-14
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05327010 2026-04-14
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05372614 2026-04-14
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT05821556 2026-04-14
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
National Cancer Institute, Naples
Phase 2 Recruiting
NCT07528430 2026-04-14
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
University of Maryland, Baltimore
Not yet recruiting
NCT07529314 2026-04-14
RI-LieF
Hospices Civils de Lyon
Phase NA Not yet recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02298959 2026-04-13
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02595931 2026-04-13
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02718001 2026-04-13
Edwards EVOQUE Eos MISCEND Study
Edwards Lifesciences
Phase NA Active not recruiting
NCT03030378 2026-04-13
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03502733 2026-04-13
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT03907475 2026-04-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03911388 2026-04-13
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03994796 2026-04-13
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT04068194 2026-04-13
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04317105 2026-04-13
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04387656 2026-04-13
NCI COVID-19 in Cancer Patients, NCCAPS Study
National Cancer Institute (NCI)
Active not recruiting
NCT04550494 2026-04-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04585958 2026-04-13
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting